leadf
logo-loader
viewAsterion Cannabis Inc

Asterion Cannabis wins medicinal cannabis licences from the Australian Office of Drug Control

CEO Stephen Van Deventer said it’s a “major milestone” as Asterion gears up to start work on its cannabis facility

Asterion Cannabis wins medicinal cannabis licences from the Australian Office of Drug Control
The company also recently received the required Development Approval (DA) permit from the regional council for the project

Asterion Cannabis Inc said Monday that its wholly-owned Australian subsidiary Asterion Australia has received its licences for the cultivation, manufacturing and research of medicinal cannabis from the Australian government's Office of Drug Control. 

In a statement, the privately-owned Canadian medicinal cannabis company said the licence was effective from December 20. 

"This is a major milestone for Asterion as it prepares to commence work on its industry leading medicinal cannabis cultivation and processing facility near Toowoomba in south east Queensland, Australia," said Asterion Cannabis CEO Stephen Van Deventer.

READ: Asterion Cannabis submits Operational Works permit application for its Toowoomba Medicinal Cannabis project

"Asterion is delighted that it has passed through the ODC's rigorous assessment process and been awarded the licences it requires to establish its flagship project,” he added.

The company said the nod from the Office of Drug Control is a “major step” for Asterion towards manufacturing pharmaceutical-grade medicinal cannabis at its planned 75 hectare (185 acre) site that includes 400,000 square metres (4.3 million square feet) of glasshouse modules for cannabis processing and cultivation and 108,000 square metres (1.2 million square feet) of auxiliary and processing buildings, along with a world-class medicinal cannabis tissue culture propagation facility, research and quality assurance labs and advanced security systems.

"Asterion intends to commence work on the Toowoomba Facility in the first quarter of 2020 and is expected to commence cultivation of its first crop in 2022,” said Van Deventer.

“On completion, the Toowoomba Facility is expected to employ more than 1,000 people harvesting more than 20,000 plants a day, and to generate an estimated AUD$2 billion annually in exports, while also supplying medicinal cannabis to the Australian market,” he added.

The licences authorize Asterion Australia to cultivate cannabis plants and process them into a range of medicinal cannabis products, including natural dried cannabis flower, across a variety of strains, aimed at specific medical conditions, as well as gel capsules, oils and soluble gels.

Asterion Cannabis is currently a privately-owned medicinal-cannabis producer with operations in Australia, specializing in medical cannabis and focused on producing the highest quality of genetically uniform cannabis strains, at an affordable price. It is looking to construct the world's largest purpose-built greenhouse cannabis production facility in Queensland, Australia.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Asterion Cannabis Inc named herein, including the promotion by the Company of Asterion Cannabis Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Asterion Cannabis feels ready to fill some gaps in the...

Asterion Cannabis President and COO Hamish Sutherland joined Steve Darling from Proactive Vancouver on Skype to talk about the company moving their large cannabis project along in Australia and how this market has lost a big player which could be an opportunity for Asterion.  Sutherland...

on 22/10/19

2 min read